Number of minutes <3 mmol/L per week in type 2 diabetes patients on different glucose-lowering agents before and after adjusting for HbA1c and clinical features
| Variables | Minutes <3 mmol/L (95% CI) | Duration ratio (vs metformin) | P value | |
| Model 1 R2=0.05 | Metformin (Ref) | 146.0 (60.6 to 231.3) | 1.0 | |
| SU | 206.7 (119.2 to 294.2) | 1.4 (0.7 to 2.9) | 0.345 | |
| Insulin | 365.9 (229.9 to 501.9) | 2.5 (1.3 to 5.0) | 0.009 | |
| Model 2 R2=0.23 | Metformin | 74.0 (14.6 to 133.4) | 1.0 | |
| SU | 156.9 (97.6 to 216.3) | 2.1 (0.9 to 4.7) | 0.067 | |
| Insulin | 405.7 (262.1 to 549.3) | 5.5 (2.4 to 12.6) | <0.001 | |
| Model 3 | Metformin | 96.4 (20.2 to 172.6) | 1.0 | |
| R2=0.30 | SU | 157.5 (97.6 to 217.4) | 1.6 (0.7 to 3.6) | 0.230 |
| Insulin | 355.0 (212.7 to 497.2) | 3.7 (1.5 to 9.3) | 0.006 |
Model 1: unadjusted; model 2: adjusted for HbA1c; model 3: adjusted for HbA1c, age, diabetes duration, BMI, sex, and renal impairment. Adjusted minutes <3 mmol/L are adjusted to the mean value for the covariate for the cohort (mean cohort HbA1c 73.2 mmol/mol). 95% CIs are shown in the parentheses. Renal impairment was defined as an estimated glomerular filtration rate <60 mL/min/1.73 m2.
Values shown are mean (95 % CIs) and p-value. Bold values denote statistical significance at the p < 0.005 level.
BMI, body mass index; HbA1c, glycated haemoglobin; SU, sulphonylurea.